Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Net Cash Flow (2016 - 2025)

Ptc Therapeutics has reported Net Cash Flow over the past 14 years, most recently at $302.2 million for Q4 2025.

  • Quarterly results put Net Cash Flow at $302.2 million for Q4 2025, up 14.41% from a year ago — trailing twelve months through Dec 2025 was $180.3 million (down 6.27% YoY), and the annual figure for FY2025 was $180.3 million, down 6.27%.
  • Net Cash Flow for Q4 2025 was $302.2 million at Ptc Therapeutics, up from -$340.7 million in the prior quarter.
  • Over the last five years, Net Cash Flow for PTCT hit a ceiling of $695.2 million in Q1 2025 and a floor of -$476.4 million in Q2 2025.
  • Median Net Cash Flow over the past 5 years was -$7.8 million (2021), compared with a mean of $38.7 million.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 4371.86% in 2022 and later crashed 536.62% in 2025.
  • Ptc Therapeutics' Net Cash Flow stood at $3.8 million in 2021, then skyrocketed by 4371.86% to $169.4 million in 2022, then skyrocketed by 151.35% to $425.8 million in 2023, then tumbled by 37.95% to $264.2 million in 2024, then grew by 14.41% to $302.2 million in 2025.
  • The last three reported values for Net Cash Flow were $302.2 million (Q4 2025), -$340.7 million (Q3 2025), and -$476.4 million (Q2 2025) per Business Quant data.